ProCE Banner Activity

Alliance A021101: Preoperative mFOLFIRINOX + Chemoradiation in Borderline Resectable Pancreatic Cancer

Slideset Download
Conference Coverage
In this pilot study, mFOLFIRINOX and chemoradiation were shown to be tolerable and allowed most patients to go on to resection.

Released: June 03, 2015

Expiration: June 01, 2016

No longer available for credit.

Share

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

AstraZeneca

Bayer Healthcare Pharma

Bristol Myers Squibb

Celgene

Genentech BioOncology

Incyte

Novartis Pharmaceuticals Corporation